Fecal Microbiota Transplantation and Newly Diagnosed Ulcerative Colitis (UC)

NCT ID: NCT04687150

Last Updated: 2022-10-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this FinUC study we are trying to find out the efficacy and safety of the Fecal microbiota transplantation (FMT) in newly diagnosed active ulcerative colitis patients. The study group with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit. The control group will be given colored water. The main aim of the FinUC study is to determine how the FMT change of the gut microbiota composition in newly diagnosed active ulcerative colitis patients. The other aim is to determine efficacy and mechanisms of fecal microbiota transplantation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized placebo-controlled pilot study. Accrued participants were randomized 1:1 using a computer generated randomization algorithm (www.random.org).
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
e

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The study group

The study group with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit

Group Type ACTIVE_COMPARATOR

Fecal microbiota transplantation

Intervention Type OTHER

Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank

The control group

The control group will be given colored water at same timepoints

Group Type PLACEBO_COMPARATOR

Colored water

Intervention Type OTHER

Colored water (placebo)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal microbiota transplantation

Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank

Intervention Type OTHER

Colored water

Colored water (placebo)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years
* Active newly diagnosed colitis (Mayo score \<11)
* Signed informed consent

Exclusion Criteria

* Fulminant severe colitis (Mayo score 11-12 or Truelove and Witts criteria)
* Gastrointestinal infection
* Pregnancy
* Antibiotic therapy at the baseline
* On-going probiotic medication
* Unable to provide signed informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Helsinki University Central Hospital

OTHER

Sponsor Role collaborator

Päijänne Tavastia Central Hospital

OTHER

Sponsor Role collaborator

Turku University Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kimmo Salminen

MD, PhD, Specialist in Gastroenterology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kimmo K Salminen, MD,PhD

Role: STUDY_DIRECTOR

Head of the section

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kimmo Salminen

Turku, , Finland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Finland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kimmo K Salminen, MD, PhD

Role: CONTACT

+35823130691

Jaakko Rautakorpi, MD

Role: CONTACT

+358238027

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kimmo K Salminen, MD, PhD

Role: primary

+35823130691

Jaakko Rautakorpi, MD

Role: backup

+35823138027

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

T298/2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fecal Transplant for Ulcerative Colitis
NCT03948919 COMPLETED PHASE1
Transfer of Feces in Ulcerative Colitis 2
NCT05998213 RECRUITING PHASE2
FMT for Postop Crohn's Disease
NCT05248191 COMPLETED PHASE1